Current Science

Open Access Open Access  Restricted Access Subscription Access

Cancer Pathology:Panel of Diagnostic Markers for Cancer


Affiliations
1 Shri Jagdishprasad Jhabarmal Tibrewala University, Vidyanagari 333 001, India
 

Cancer is the second known lethal disorder after coronary heart disease, characterized by the loss of control of cell growth leading to excessive proliferation and spread of cells. Different diagnostic tools and different protein or glycoprotein markers are available for diagnostic utility and prognosis of cancer in patients. Of these, some diagnostic markers are promising but some still need to be validated for their utility. In this study, we demonstrate the pathogenesis of different types of cancer, such as cancer of breast tissue, pancreatic tissue, ovary, prostate, lung tissue and colorectal tract and the utility of a panel of diagnostic markers for them.

Keywords

Diagnostic Marker, Glycoprotein, Pathogenesis, Protein.
User
Notifications
Font Size

  • Radic, S., Stanojevic, Z. and Dindic, B., The pathogenesis of neoplasia. Arch. Oncol., 2004, 12, 1–3.

  • Bhatt, A. N., Mathur, R., Farooque, A., Verma, A. and Dwarakanath, B. S., Cancer biomarkers – current perspectives. Indian J. Med. Res., 2010, 132, 129–149.

  • Yuspa, S. H., The pathogenesis of squamous cell cancer, lessons learned from studies of skin carcinogenesis. Cancer Res., 1994, 54, 1178–1189.

  • Bauer, J. H. and Hefand, S. L., New tricks of an old molecule, lifespan regulation by p53. Aging Cell, 2006, 5, 437–440.

  • Smilek, P. et al., Epidermal growth factor receptor (EGFR) expression and mutations in the EGFR signalling pathway in correlation with anti-EGFR therapy in head and neck squamous cell carcinomas. Neoplasma, 2012, 59, 508–515.

  • Ang, K. K. et al., Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res., 2002, 62, 7350–7356.

  • Ayuso-Sacido, A. et al., Activated EGFR signaling increases proliferation, survival, and migration and blocks neuronal differentiation in post-natal neural stem cells. J. Neurooncol., 2009, 97, 323–337.

  • Pelloski, C. et al., YKL-40 expression is associated with poorer response to radiation and shorter overall survival in glioblastoma. Clin. Cancer Res., 2005, 11, 3326–3334.

  • Jung, C. et al., Serum GFAP is a diagnostic marker for glioblastoma multiforme. Brain, 2007, 130, 3336–3341.

  • Levin, V. A., Leibel, S. A. and Gutin, P. H., Neoplasms of the central nervous system. In Cancer, Principles and Practice of Oncology (eds DeVita, V. T., Hellman, S. and Rosenberg, S. A.), Lippincott Williams & Wilkins, Philadelphia (PA), 2091–2100, 6th edn, p. 200.

  • Bradley, S. V., Holland, E. C., Liu, G. Y., Thomas, D., Hyun, T. S. and Ross, T. S., Huntingtin interacting protein 1 is a novel brain tumour marker that associates with epidermal growth factor receptor. Cancer Res., 2007, 67, 3609–3615.

  • Gharib, H. and Papini, E., Thyroid nodules: clinical importance, assessment and treatment. Endocrinol. Metab. Clin. North Am., 2007, 36, 707–735.

  • Holyoke, E. D. et al., Biologic markers in cancer diagnosis and treatment. Curr. Probl. Cancer, 1981, 6, 1–68.

  • d’Herbomez, M. et al., Reference range of serum calcitonin levels in humans, influence of calcitonin assays, sex, age, and cigarette smoking. Eur. J. Endocrinol., 2007, 157, 749–755.

  • van Veelen, W. et al., Medullary thyroid carcinoma and biomarkers, past, present and future. J. Intern. Med., 2009, 266, 126–140.

  • Whitley, R. J. and Ain, K. B., Thyroglobulin, a specific serum marker for the management of thyroid carcinoma. Clin. Lab. Med., 2004, 24, 29–47.

  • Gupta, M. and Chia, S. Y., Circulating thyroid cancer markers. Curr. Opin. Endocrinol. Diabetes Obes., 2007, 14, 383–388.

  • Inohara, H. et al., Expression of galectin-3 in fine-needle aspirates as a diagnostic marker differentiating benign from malignant thyroid neoplasms. Cancer, 1999, 85, 2475–2484.

  • Szabo, C. I. and King, M. C., Inherited breast and ovarian cancer. Hum. Mol. Genet., 1995, 4, 1811–1817.

  • Duffy, M. J., Serum tumour markers in breast cancer, are they of clinical value? Clin. Chem., 2006, 52, 345–351.

  • Maric, P., Ozretic, P., Levanat, S., Oreskovic, S., Antunac, K. and Beketic-Oreskovic, L., Tumour markers in breast cancerevaluation of their clinical usefulness. Coll. Antropol., 2011, 35, 241–247.

  • Gupta, A. K. et al., Development of monoclonal antibodies against MUC1/Y recombinant protein expressed in E. coli. Int. J. Pharm. Biol. Sci., 2015, 6, 37–46.

  • Gupta, A. K., Kaur, P., Patil, H., Kadam, P., Bhanushali, P. B. and Chugh, M., Development of monoclonal antibodies against CMPNacetylneuraminate-beta-galactosamide-alpha-2,3-sialyltransferase 1 (ST3GAL1) recombinant protein expressed in E. coli. Biochem. Res. Int., 2015, 2015, 1–7.

  • Gupta, A. K. and Khadke, P., Co-expression and Regulation of p53 and MUC1 in human carcinomas. Int. J. Curr. Res., 2015, 7, 21127–21132.

  • Wang, Z. et al., Mammaglobin, a valuable diagnostic marker for metastatic breast carcinoma. Int. J. Clin. Exp. Pathol., 2009, 2, 384–389.

  • Gupta, A. K., Kaur, P., Bhanushali, P. B. and Khadke, P., Multifunctional diagnostic exploitation of human Galectin-3. Int. J. Pharm. Sci. Rev. Res., 2015, 32, 26–37.

  • Al-Joudi, F. S., et al., Expression of survivin and its clinicpathological correlations in invasive ductal carcinoma of the breast. Singapore Med. J., 2007, 48, 607–614.

  • Jarvinen, T. A., Pelto-Huikko, M., Holli, K. and Isola, J., Estrogen receptor beta is coexpressed with ER alpha and PR and associated with nodal status, grade, and proliferation rate in breast cancer. Am. J. Pathol., 2000, 156, 29–35.

  • Molina, R. et al., Tumour markers in breast cancer – European group on tumour markers recommendations. Tumour Biol., 2005, 26, 281–293.

  • O’Brien, N. et al., Use of a panel of novel genes for differentiating breast cancer from non-breast tissues. Tumour Biol., 2007, 28, 312–317.

  • Maass, N., Nagasaki, K., Ziebart, M., Mundhenke, C. and Jonat, W., Expression and regulation of tumour suppressor gene maspin in breast cancer. Clin. Breast Cancer, 2002, 3, 281–287.

  • Incorvati, J. A., Shah, S., Mu, Y. and Lu, J., Targeted therapy for HER2 positive breast cancer. J. Hematol. Oncol., 2013, 6, 1–9.

  • Pinhel, S. et al., ER and HER2 expression are positively correlated in HER2 non-overexpressing breast cancer. Breast Cancer Res., 2012, 14, 1–12.

  • Wingo, P. A., Tong, T. and Bolden, S., Cancer statistics. CA Cancer J. Clin., 1995, 45, 8–30.

  • Indovina, P., Marcelli, E., Pentimalli, F., Tanganelli, P., Tarro, G. and Giordano, A., Mass spectrometry-based proteomics, the road to lung cancer biomarker discovery. Mass Spectrom. Rev., 2013, 32, 129–142.

  • Ahn, J. M. and Cho, J. Y., Current serum lung cancer biomarkers. J. Mol. Biomark. Diagn., 2013, S4: 001, 1–7.

  • Cho, W. C., Potentially useful biomarkers for the diagnosis, treatment and prognosis of lung cancer. Biomed. Pharmac. Other., 2007, 61, 515–519.

  • Ferrigno, D., Buccheri, G. and Giordano, C., Neuron-specific enolase is an effective tumour marker in non-small cell lung cancer (NSCLC). Lung Cancer, 2003, 41, 311–320.

  • Schneider, J., Tumour markers in detection of lung cancer. Adv. Clin. Chem., 2006, 42, 1–41.

  • Kulpa, J., Wojcik, E., Reinfuss, M. and Kolodziejski, L., Carcinoembryonic antigen, squamous cell carcinoma antigen, CYFRA 21-1, and neuron-specific enolase in squamous cell lung cancer patients. Clin. Chem., 2002, 48, 1931–1937.

  • Tsavans, N. et al., Carcinoembryonic antigen (CEA), alphafetoprotein, CA19-9 and CA125 in advanced colorectal cancer (ACC). Int. J. Biol. Markers, 1993, 8, 88–93.

  • Munck-Wikland, E., Kuylenstierna, R., Wahren, B., Lindholm, J. and Haglund, S., Tumour markers carcinoembryonic antigen, CA 50, and CA 19-9 and squamous cell carcinoma of the esophagus. Cancer (Phila.), 1988, 62, 2281–2286.

  • Parkin, D. M., Bray, F., Ferlay, J. and Pisani, P., Global cancer statistics, 2002. CA Cancer J. Clin., 2005, 55, 74–108.

  • Doweck, I. et al., Cyfra 21-1, A new potential tumour marker for squamous cell carcinoma of head and neck. Arch. Otolaryngol. Head Neck Surg., 1995, 121, 177–181.

  • Nakata, B. et al., Clinical significance of serum CYFRA 21-1 in gastric cancer. Br. J. Cancer, 1996, 73, 1529–1532.

  • Chen, D. S., Sung, J. L. and Sheu, J. C., Serum -fetoprotein in the early stage of human hepatocellular carcinoma. Gastroenterology, 1984, 86, 1404–1409.

  • Khien, V. V. et al., Clinical evaluation of lentil lectin-reactive alpha-fetoprotein-L3 in histology proven hepatocellular carcinoma. Int. J. Biol. Markers., 2001, 16, 105–111.

  • Nakatsura, T. et al., Glypican-3, overexpressed specifically in human hepatocellular carcinoma, is a novel tumour marker. Biochem. Biophys. Res. Commun., 2003, 306, 16–25.

  • Guido, M. et al., Squamous cell carcinoma antigen in human liver carcinogenesis. J. Clin. Pathol., 2008, 61, 445–447.

  • Zhang, Y., Deng, Z. S., Liao, M. M., Wang, N., Zhang, X. Q. and Yu, H. Y., Tumour associated glycoprotein-72 is a novel marker for poor survival in hepatocellular carcinoma. Pathol. Oncol. Res., 2012, 18, 911–916.

  • Zhou, L., Liu, J. and Luo, F., Serum tumour markers for detection of hepatocellular carcinoma. World J. Gastroenterol., 2006, 12, 1175–1181.

  • Rosewicz, S. and Wiedenmann, B., Pancreatic carcinoma. Lancet, 1997, 349, 485–489.

  • Chung, M. H., Gupta, R. K., Essner, R., Ye, W., Yee, R. and Morton, D. L., Serum TA90 immune complex assay can predict outcome after resection of thick (≥4 mm) primary melanoma and sentinel lymphadenectomy. Ann. Surg. Oncol., 2002, 9, 120–126.

  • Podolsky, D. K., Serologic markers in the diagnosis and management of pancreatic carcinoma. World J. Surg., 1984, 8, 822–830.

  • Johansson, C., Nilsson, O., Baeckstrom, D., Jansson, E. L. and Lindholm, L., Novel epitopes on the CA50-carrying antigen, chemical and immunochemical studies. Tumour Biol., 1991, 12, 159–170.

  • Melo, S. A. et al., Glypican-1 identifies cancer exosomes and detects early pancreatic cancer. Nature, 2015, 523, 177–182.

  • Sardana, G., Jung, K., Stephan, C. and Diamandis, E. P., Proteomic analysis of conditioned media from the PC3, LNCaP, and 22Rv1 prostate cancer cell lines, discovery and validation of candidate prostate cancer biomarkers. J. Proteome Res., 2008, 7, 3329–3338.

  • Cooner, W. H. et al., Prostate cancer detection in a clinical urological practice by ultrasonography, digital rectal examination and prostate specific antigen. J. Urol., 1990, 143, 1146–1154.

  • Kattan, M. W. et al., The addition of interleukin-6 soluble receptor and transforming growth factor beta1 improves a preoperative nomogram for predicting biochemical progression in patients with clinically localized prostate cancer. J. Clin. Oncol., 2003, 21, 3573–3579.

  • Netto, G. J. and Cheng, L., Emerging critical role of molecular testing in diagnostic genitourinary pathology. Arch. Pathol. Lab. Med., 2012, 136, 372–390.

  • Cazares, L. H., Drake, R. R., Esquela-Kirscher, A., Lance, R. S., Semmes, O. J. and Troyer, D. A., Molecular pathology of prostate cancer. Cancer Biomark., 2010, 9, 441–459.

  • Salami, S. S. et al., Combining urinary detection of TMPRSS2, ERG and PCA3 with serum PSA to predict diagnosis of prostate cancer. Urol. Oncol., 2013, 31, 566–571.

  • Martin, N. E., Mucci, L. A., Loda, M. and Depinho, R. A., Prognostic determinants in prostate cancer. Cancer J., 2011, 17, 429–437.

  • Agarwal, M., He, C., Siddiqui, J., Wei, J. and Macoska, J. A., CCL11 (Eotaxin-1), A new diagnostic serum marker for prostate cancer. Prostate, 2013, 73, 573–581.

  • Abrahamsson, P. A., Lilja, H., Falkmer, S. and Wadstrom, L. B., Immunohistochemical distribution of the three predominant secretory proteins in the parenchyma of hyperplastic and neoplastic prostate glands. Prostate, 1988, 12, 39–46.

  • Dahlman, A., Rexhepaj, E., Brennan, D. J., Gallagher, W. M., Gaber, A. and Lindgren, A., Evaluation of the prognostic significance of MSMB and CRISP3 in prostate cancer using automated image analysis. Modern Pathol., 2011, 24, 708–719.

  • Rieger, A. and Wahren, B., CEA levels at recurrence and metastases, importance for detecting secondary disease. Scand. J. Gastroenterol., 1975, 10, 869–874.

  • Bhatnagar, J., Tewari, H., Bhatnagar, M. and Austin, G. E., Comparison of carcinoembryonic antigen in tissue and serum with grade and stage of colon cancer. Anticancer Res., 1999, 19, 2181–2188.

  • Guadagni, F. et al., CA 72-4 serum marker-a new tool in the management of carcinoma patients. Cancer Invest., 1995, 13, 227–238.

  • Kato, M., Maeta, H., Kato, S., Shinozawa, T. and Terada, T., Immunohistochemical and in situ hybridization analyses of midkine expression in thyroid papillary carcinoma. Mod. Pathol., 2000, 13, 1060–1065.

  • Ikematsu, S. et al., Serum midkine levels are increased in patients with various types of carcinomas. Br. J. Cancer, 2000, 83, 701–706.

  • Wald, M. et al., Bladder tumour antigen stat test in non-urothelial malignant urologic conditions. Isr. Med. Assoc. J., 2002, 4, 174–175.

  • Murphy, W. M., Rivera-Ramirez, I., Medina, C. A., Wright, N. J. and Wajsman, Z., The bladder tumour antigen (BTA) test compared to voided urine cytology in the detection of bladder neoplasms. J. Urol., 1997, 158, 2102–2106.

  • Hajdinjak, T., UroVysion FISH test for detecting urothelial cancers, Meta-analysis of diagnostic accuracy and comparison with urinary cytology testing. Urol. Oncol., 2008, 26, 646–651.

  • Zurawski Jr, V. R., Orjaseter, H., Andersen, A. and Jellum, E., Elevated serum CA 125 levels prior to diagnosis of ovarian neoplasia, relevance for early detection of ovarian cancer. Int. J. Cancer, 1988, 42, 677–680.

  • Mastropaolo, W., Fernandez, Z. and Miller, E. L., Pronounced increases in the concentration of an ovarian tumour marker, CA-125, in serum of a healthy subject during menstruation. Clin. Chem., 1986, 32, 2110–2111.

  • Disis, M. L., Pupa, S. M., Gralow, J. R., Dittadi, R., Menard, S. and Cheever, M. A., High-titer HER-2/neu protein-specific antibody can be detected in patients with early-stage breast cancer. J. Clin .Oncol., 1997, 15, 3363–3367.

  • Gadducci, A. et al., Assessment of the prognostic relevance of serum anti-p53 antibodies in epithelial ovarian cancer. Gynecol. Oncol., 1999, 72, 76–81.

  • Rein, B. J. D., Gupta, S., Dada, R., Safi, J., Michener, C. and Agarwal, A., Potential markers for detection and monitoring of ovarian cancer. J. Oncol., 2011, 475983, 1–17.

  • Moore, R. G. et al., The use of multiple novel tumour biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecologic Oncol., 2008, 108, 402–408.

  • Kelley, M. C., Gupta, R. K., Hsueh, E. C., Yee, R., Stern, S. and Morton, D. L., Tumour-associated antigen TA90 immune complex assay predicts recurrence and survival after surgical treatment of stage I-III melanoma. J. Clin. Oncol., 2001, 19, 1176–1182.

  • Kelley, M. C. et al., Tumour-associated antigen TA-90 immune complex assay predicts subclinical metastasis and survival for patients with early stage melanoma. Cancer, 1998, 83, 1355–1361.

  • Meral, R. et al., Prognostic significance of melanoma inhibiting activity levels in malignant melanoma. Melanoma Res., 2001, 11, 627–632.

  • Cochran, A. J., Wen, D. R., Herschman, H. R. and Gaynor, R. B., Detection of S-100 protein as an aid to the identification of melanocytic tumours. Int. J. Cancer, 1982, 30, 295–297.

  • Bonfrer, J. M., Korse, C. M., Nieweg, O. E. and Rankin, E. M., The luminescence immunoassay S-100, a sensitive test to measure circulating S-100B, its prognostic value in malignant melanoma. Br. J. Cancer, 1998, 77, 2210–2214.

  • Bosserhoff, A. K., Dreau, D., Hein, R., Landthaler, M., Holder, W. D. and Buettner, R., Melanoma inhibitory activity (MIA), a serological marker of malignant melanoma. Rec. Res. Can. Res., 2001, 158, 158–168.

  • Guba, M. et al., Overexpression of melanoma inhibitory activity (MIA) enhances extravasation and metastasis of A-mel 3 melanoma cells in vivo. Br. J. Cancer, 2000, 83, 1216–1222.

  • Chua, S. C., Rozalli, F. I. and O’Connor, S. R., Imaging features of primary extranodal lymphomas. Clin. Radiol., 2009, 64, 574–588.

  • Yoo, C., Yoon, D. H. and Suh, C., Serum beta-2 microglobulin in malignant lymphomas: an old but powerful prognostic factor. Blood Res., 2014, 49, 148–153.

  • Schneider, R. J. et al. Prognostic significance of serum lactate dehydrogenase in malignant lymphoma. Cancer, 1980, 46, 139–143.

  • Romana, S. P. et al., High frequency of t(12,21) in childhood B-lineage acute lymphoblastic leukemia. Blood, 1995, 86, 4263–4269.

  • Abali, H. et al., Circulating and local bone marrow reninangiotensin system in leukemic hematopoiesis, preliminary evidences. Hematology, 2002, 7, 75–82.

  • Wulf, G.G. et al., Renin in acute myeloid leukaemia blasts. Br. J. Haematol., 1998, 100, 335–337.

  • Teresa Gomez Casares, M. et al., Renin expression in hematological malignancies and its role in the regulation of hematopoiesis. Leuk. Lymphoma., 2002, 43, 2377–2381.

  • Marella, S., Prognostic and predictive markers in early detection of different types of cancers for selected organ sites. IOSR-JPBS, 2013, 8, 25–42.

  • Zhao, Y., Huang, H. and Wei, G., Novel agents and biomarkers for acute lymphoid leukemia. J. Hematol. Oncol., 2013, 6, 1–11.


Abstract Views: 407

PDF Views: 118




  • Cancer Pathology:Panel of Diagnostic Markers for Cancer

Abstract Views: 407  |  PDF Views: 118

Authors

Anuj Kumar Gupta
Shri Jagdishprasad Jhabarmal Tibrewala University, Vidyanagari 333 001, India
Prashant Khadke
Shri Jagdishprasad Jhabarmal Tibrewala University, Vidyanagari 333 001, India

Abstract


Cancer is the second known lethal disorder after coronary heart disease, characterized by the loss of control of cell growth leading to excessive proliferation and spread of cells. Different diagnostic tools and different protein or glycoprotein markers are available for diagnostic utility and prognosis of cancer in patients. Of these, some diagnostic markers are promising but some still need to be validated for their utility. In this study, we demonstrate the pathogenesis of different types of cancer, such as cancer of breast tissue, pancreatic tissue, ovary, prostate, lung tissue and colorectal tract and the utility of a panel of diagnostic markers for them.

Keywords


Diagnostic Marker, Glycoprotein, Pathogenesis, Protein.

References





DOI: https://doi.org/10.18520/cs%2Fv112%2Fi09%2F1831-1838